VAIM

VAIM Co., Ltd. is the South Korean company that presents Juvelook as its principal product brand and operates the current five-product Korean Juvelook portfolio. Regulator records also identify VAIM as the manufacturer of specified Juvelook and Lenisna presentations in particular markets. Those records do not establish that every Korean variant has the same registration, name, importer, or intended use outside South Korea.

Direct answer

Company and brand relationship: VAIM’s current Korean site names the company as 주식회사 바임 and presents Juvelook as its own product brand.
Korean portfolio: Juvelook i, Juvelook Skin, Juvelook, Juvelook Volume, and Juvelook G are the five products currently displayed by VAIM in South Korea.
Manufacturing evidence: Philippine and Russian regulator records identify VAIM as manufacturer of the exact Juvelook presentations recorded there; the Russian record also identifies VAIM for Lenisna 200.
Lenisna boundary: Lenisna remains a regulator-recorded name in some international markets. It should not be replaced globally with Juvelook Volume merely because VAIM previously described a Korean brand consolidation.
Safety-notice boundary: the European field-safety action discussed below concerns Juvelook, lot VJ220511, and an update restricting use in the periorbital area. It is not evidence of a recall of all Juvelook or VAIM products.

Company-role matrix

Product and market	VAIM role supported by the record	Registration or commercial context	Other named party
Current Korean Juvelook family	Product company and brand operator; official site presents all five products	VAIM describes the products as Korean Class IV medical devices and supplies one Korean intended-use statement across the displayed family	Not stated on the product page
Juvelook soft-tissue injectable implant, Philippines	Manufacturer, including the named Okcheon manufacturing rooms	`CMDR-2024-03133B`, issued August 8, 2024 and expiring August 8, 2029	Elogio Asia Philippines Inc., importer/distributor
Juvelook 50 mg and Lenisna 200, Russia	Manufacturer; Daejeon and Okcheon are listed as production sites	Registration certificate `RZN 2024/23973`, dated November 19, 2024, records the two presentations	Market-specific authorized-representative context in the registry
Juvelook 50 mg and Lenisna 200, Colombia	Manufacturer named in safety report under registration `2023DM-0027970`	The report distinguishes Juvelook 50 mg from Lenisna 200	Bio On Pharma SAS, importer

This matrix states only the role supported in each named source. Portfolio control does not by itself prove physical manufacture, approval-holder status, or distribution rights in another market.

Current Korean Juvelook portfolio

VAIM’s official Korean product page 🔗 lists the same PDLLA-to-HA mass ratio across five products while preserving separate names and presentations:

Korean product name	Total vial content	Declared components	What the official page establishes
Juvelook i	30 mg	PDLLA 25.5 mg + HA 4.5 mg	A distinct named Korean product presentation
Juvelook Skin	30 mg	PDLLA 25.5 mg + HA 4.5 mg	A distinct named Korean product presentation, despite the same declared quantities as Juvelook i
Juvelook	50 mg	PDLLA 42.5 mg + HA 7.5 mg	The core 50 mg presentation
Juvelook Volume	200 mg	PDLLA 170 mg + HA 30 mg	A distinct 200 mg presentation
Juvelook G	200 mg	PDLLA 170 mg + HA 30 mg	A distinct named Korean product presentation, despite the same declared quantities as Juvelook Volume

For all five entries, the page gives the Korean intended use as subcutaneous injection of polylactide and hyaluronic acid for temporary improvement of adult facial wrinkles through physical restoration. This wording should not be transferred to another country without that market’s label or registration record.

Equal component quantities do not establish identical particle characteristics, preparation, placement, or clinical role. The Juvelook product-family page keeps those product-level distinctions separate.

VAIM announced Juvelook i and Juvelook G as new products in 2025 🔗, then described a five-product lineup when Juvelook Skin launched in June 2026 🔗. These are company portfolio statements, not substitutes for individual regulator records.

Juvelook, Juvelook Volume, and Lenisna are region-sensitive names

An official VAIM-hosted account of an earlier relaunch says Raum Medical became VAIM Global and that the Juvelook and Lenisna brands were consolidated in Korea as Juvelook and Juvelook Volume (VAIM brand-relaunch account 🔗). That commercial history does not create a universal regulatory alias.

Current regulator examples preserve the boundary:

Russia’s Roszdravnadzor device record 🔗 separately lists Juvelook as a 50 mg vial and Lenisna 200 as a 200 mg vial under one November 19, 2024 registration.
Colombia’s Invima safety report 308-2024 🔗 likewise records Juvelook 50 mg and Lenisna 200 as separate presentations under registration 2023DM-0027970.

Accordingly, Lenisna, Lenisna 200, and Juvelook Volume should be treated as source- and market-specific identities. A shared company, 200 mg content, or commercial lineage is not enough to claim that labels, instructions, or approvals are interchangeable.

Regional manufacturing and registration evidence

The Philippines FDA record for CMDR-2024-03133B 🔗 identifies:

the registered product as Juvelook Soft Tissue Injectable Implant;
VAIM Co., Ltd. as manufacturer;
Korea as country of origin;
named addresses in Okcheon and Daejeon, including specific Okcheon manufacturing rooms; and
Elogio Asia Philippines Inc. as importer/distributor.

Russia’s registration certificate independently lists VAIM production sites in Daejeon and Okcheon for the Juvelook 50 mg and Lenisna 200 presentations. Together, these records support a physical-manufacturer role for the products and markets they name. They do not establish one global approval, one global importer, or registration of Juvelook i, Skin, Volume, and G in the Philippines or Russia.

Product-specific European field-safety action

The Italian Ministry of Health record 🔗 identifies VAIM as manufacturer, the affected device as Soft Tissue Injectable Implant Juvelook, reference 308653, and the action type as safety information. The ministry received the notice on September 3, 2024 and last updated its record on December 2, 2025.

The linked manufacturer field-safety notice, also archived by Germany’s BfArM 🔗, narrows the action further:

Scope item	Documented limit
Product	Juvelook soft-tissue injectable implant
UDI-DI	`(01)08800051300102`
Affected lot	`VJ220511`
Triggering event	Large thickenings described after administration around the eye on July 3, 2023
Identified information problem	The IFU did not clearly delimit safe and non-safe areas or the restriction on eyelid use
Corrective scope	IFU/safety information stating that Juvelook should not be used in the periorbital area

The notice does not name Juvelook Volume, Lenisna, Juvelook i, Juvelook Skin, or Juvelook G as affected products. It also does not support a conclusion that all lots were recalled. A January 9, 2025 Polish regulator notice 🔗 separately publishes VAIM safety note VAIM-FSCA-03 on avoiding Juvelook use around the eyes.

Interpretation boundaries

Do not use VAIM’s company or manufacturing role to infer:

one preparation protocol for all five Korean presentations;
one global intended use or placement plane;
automatic equivalence between Lenisna 200 and Juvelook Volume;
registration of the whole Korean portfolio wherever Juvelook appears in a regulator record;
clinical superiority from product size or particle claims; or
simple reversibility of the complete implant because HA is one component.

Juvelook provides the product-family formulation and preparation comparison.
PDLLA explains why shared PDLLA does not make different product systems interchangeable.
AestheFill versus Juvelook separates the REGEN Biotech and VAIM product architectures.
Juvelook versus Juvelook Volume compares the two named Korean presentations without deriving instructions from their four-fold content difference.
Regional regulation separates product records and safety notices by market.
REGEN Biotech provides a separate Korean PDLLA company context.